Momentum 1 Phase 3 Clinical Trial

New Research Study Offers Anyone Ages Two and Up a Chance to Help Those with Dravet Syndrome

If a loved one has Dravet syndrome, you know that it affects the whole family. Dravet syndrome, a lifelong disease marked by prolonged, frequent seizures, requires constant care and can significantly impact quality of life for the patient and their loved ones. And because treatment options are limited, it is normal to feel frustrated and even hopeless at times.

However, science is advancing every day and researchers are looking at ways to offer people with Dravet syndrome additional treatment options that may control seizures more effectively. One way is by studying experimental treatments.

Momentum 1 is a new research study sponsored by Eisai Inc. evaluating a new potential treatment called lorcaserin. The study will determine whether adding lorcaserin to a person’s current epilepsy medication will help reduce the number of seizures in people with Dravet syndrome when compared to a sugar pill (placebo). The Momentum 1 study will take place at approximately 20 sites across the US.

This kind of research is critical to help find new solutions for families coping with Dravet syndrome, and you may be able to help. In order to be eligible for participation, your loved one needs to meet the following criteria:

  • Age two years and older
  • Confirmed diagnosis of epilepsy with Dravet syndrome

Taking part in this study offers the opportunity to possibly progress medical research and provide more information about lorcaserin that may help treat those with Dravet syndrome in the future. Your child or loved one’s personal information will remain strictly private and confidential, and participants may also be eligible to receive reimbursement for study-related travel expenses.

Any medical information collected in this study will be exclusively used for treatment development. Following this study, your loved one may also be able to join an extended access program to continue receiving lorcaserin until the product is approved.

Eisai Inc.’s goal is to develop a treatment that will enhance the lives of children living with Dravet syndrome. More information on the study and participating study locations can be found at